Literature DB >> 23847352

FDA approves radiopharmaceutical for metastatic prostate cancer.

.   

Abstract

The U.S. Food and Drug Administration approved radium-223 dichloride for treatment of men with metastatic castration-resistant prostate cancer that has spread to the bone.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23847352     DOI： 10.1158/2159-8290.CD-NB2013-088

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  2 in total

Review 1.  Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.

Authors:  Leah M Cook; Gemma Shay; Arturo Araujo; Arturo Aruajo; Conor C Lynch
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

2.  Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.

Authors:  Katja Behling; William F Maguire; José Carlos López Puebla; Shanna R Sprinkle; Alessandro Ruggiero; Joseph O'Donoghue; Philip H Gutin; David A Scheinberg; Michael R McDevitt
Journal:  J Nucl Med       Date:  2016-04-28       Impact factor: 10.057
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.